Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.44 USD | +1.92% |
|
+2.72% | +5.39% |
13/06 | Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity | MT |
13/06 | Collegium Pharmaceutical, Inc. Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.39% | 106.13Cr | |
+55.95% | 82TCr | |
+43.33% | 64TCr | |
-6.98% | 35TCr | |
+19.08% | 33TCr | |
+9.05% | 30TCr | |
+17.08% | 24TCr | |
+2.70% | 23TCr | |
+13.23% | 22TCr | |
+8.91% | 17TCr |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Pharmaceutical Insider Sold Shares Worth $2,075,086, According to a Recent SEC Filing